Pharmaceutical Technology Editors

The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.

By purchasing the BMS Sword, Ireland facility, SK Biotek will be the first South Korean company to invest in pharmaceutical manufacturing in Ireland.

The annual meeting of the Honeywell Users Group for the Americas will discuss industrial automation.

FDA Commissioner Scott Gottlieb announced the agency will hold a public meeting on drug competition as part of its Drug Competition Action Plan.

Charlie Baker announced a plan to invest up to $500 million in the MA life-science industry.

The organization released principles related to workforce development, diversity, and inclusion that it believes are key to the biotechnology industry.

The European Commission approved Rixathon for use in all indications of its reference medicine, MabThera.

The company announced its new ISQ EC Single Quadrupole mass spectrometer and the new range of Thermo Scientific MAbPac RP 1-mm columns.

The company was granted patent rights to the use of CRISPR in a genomic integration method for eukaryotic cells.

The company added new products to its InfinityLab LC Series which will be showcased at HPLC 2017 in Prague.

The company has voluntarily recalled Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level because of a lack of sterility assurance.

The company is voluntarily recalling all unexpired lots of nitroglycerin products produced at its Houston location for potency issues.

The agency’s management board discussed plans for the relocation of EMA at its June 2017 meeting.

The company recalled a variety of products due to the potential of microbial contamination.

SK Biotek plans to operate the Swords, Ireland API manufacturing facility as a contract development and manufacturing site.

Basilea Pharmaceutica International Ltd. entered into a distribution and license agreement with Pfizer and Avir Pharma Inc. to distribute Basilea’s antifungal treatments.

The companies announced an agreement where Dorizoe will work with Baxter to develop more than 20 generic injectable products.

Selexis will be integrated with KBI Biopharma, which was acquired by JSR Life Sciences in 2015.

A consent decree of permanent injunction was entered between the United States and the two companies due to unapproved, mislabeled, and adulterated drugs.

The company has extended its voluntarily recall of one lot of paliperidone extended-release tablets to the consumer level due to dissolution test failure.

Sartorius Stedim Biotech combined the company’s ambr 15 bioreactor system with the Nova BioProfile FLEX2 cell culture analyzer for laboratory experiments.

The agency sent a warning letter to A-S Medication Solutions LLC after it found the company didn’t comply with drug listing file requirements.

The companies are partnering to provide new fill/finish facilities and solutions for biopharmaceutical products.

The company added a 40,000-ft2 purpose-built R&D center at 17112 Armstrong Ave, Irvine, CA.

FDA Commissioner Scott Gottlieb announced the July meeting as part of his commitment to address opioid abuse.

FDA sent a warning letter to drug compounder DCA, Inc. dba Beacon Prescriptions for failing to ensure sanitary conditions.

Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York.

The companies are collaborating to interface the Waters Acquity QDa Mass Detector with the IonSense DART ionization source.

The company is voluntarily recalling one lot of Eliquis after a patient discovered that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets.

The company said it expects to transaction to close on June 16, 2017.